Results
|
161321.
|
|
|
161322.
|
|
|
161323.
|
|
|
161324.
|
|
|
161325.
|
|
|
161326.
|
|
|
161327.
|
|
|
161328.
|
|
|
161329.
|
|
|
161330.
|
Feasibility of poly (ϵ-caprolactone-co-DL-lactide) as a biodegradable material for in situ forming implants: evaluation of drug release and in vivo degradation. [electronic resource] by
- Zhang, Xiaowei
- Zhang, Chong
- Zhang, Wei
- Meng, Shu
- Liu, Danhua
- Wang, Ping
- Guo, Jing
- Li, Jianxin
- Guan, Yanmin
- Yang, Dan
Producer: 20151103
In:
Drug development and industrial pharmacy vol. 41
Availability: No items available.
|
|
161331.
|
|
|
161332.
|
|
|
161333.
|
|
|
161334.
|
CLC604 preferentially inhibits the growth of HER2-overexpressing cancer cells and sensitizes these cells to the inhibitory effect of Taxol in vitro and in vivo. [electronic resource] by
- Lee, Jang-Chang
- Chou, Li-Chen
- Lien, Jin-Chemg
- Wu, Jia-Chiun
- Huang, Chi-Hung
- Chung, Chao-Ho
- Lee, Fang-Yu
- Huang, Li-Jiau
- Kuo, Sheng-Chu
- Way, Tzong-Der
Producer: 20140429
In:
Oncology reports vol. 30
Availability: No items available.
|
|
161335.
|
|
|
161336.
|
|
|
161337.
|
|
|
161338.
|
|
|
161339.
|
|
|
161340.
|
|